Cure My Disease

Don't miss your cure!

 Log in / Sign up

Antibiotics before kidney drainage: help or hype?

NCT ID NCT06801405

Knowledge-focused Sponsor: Barretos Cancer Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether giving antibiotics before a kidney drainage procedure (called percutaneous nephrostomy) prevents urinary tract infections in cancer patients whose urinary tract is blocked by a tumor. Researchers reviewed records of 320 cancer patients who had the procedure. The goal was to compare infection rates between those who received preventive antibiotics and those who did not.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

320 people

The number who actually took part.

Started

Apr 2021

Finished

Oct 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients treated for cancer who required percutaneous nephrostomies

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients treated for cancer who required percutaneous nephrostomies Exclusion Criteria: * Patients and/or procedures if percutaneous nephrostomy was used to perform other procedures; * Patients and/or procedures if percutaneous nephrostomy was used to treat clinical conditions other than malignant ureteral obstruction * Patients and/or procedures if percutaneous nephrostomy was used to clear the urinary tract of non-malignant causes

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute kidney injury are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute kidney injury neoplasm ureteral obstruction urinary tract infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute kidney injury Antibiotic prophylaxis Neoplasms Nephrostomy; complications Ureteral obstruction Urinary tract infections

Contacts and locations

Locations

  • Jales Cancer Hospital

    Jales, São Paulo, 15706-396, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.